BIOMAT Database Logo BIOMAT Database Logo

cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. I. Distribution within the central nervous system after intravenous and intracarotid infusion. 1993

H Nakagawa, and T Fujita, and S Izumoto, and S Kubo, and Y Nakajima, and K Tsuruzono, and K Kodama, and M Higashiyama, and O Doi, and T Hayakawa
Department of Neurosurgery, Center for Adult Diseases, Osaka, Japan.

The distribution of cis-diamminedichloroplatinum (CDDP) was studied in 23 patients undergoing surgical resection of brain tumors metastatic from lung cancer. CDDP (100 mg/m2) was administered intravenously (i.v.) or intra-arterially (IA) at the time of surgery, and various fluids and tissues were sampled for measurement of drug concentration. Comparison of the two routes of administration disclosed that the plasma level was slightly lower after IA than after i.v. infusion, whereas there was no difference between the two routes in terms of drug diffusion into the brain tissue adjacent to the tumor. However, IA administration resulted in an intratumoral drug concentration twice as high as that achieved with i.v. infusion. The tumor:plasma and tumor:adjacent brain ratios of drug concentration after IA injection were also twice those measured after i.v. administration. The distribution pattern of CDDP is characteristic of water-soluble agents. All patients experienced tolerable nausea and vomiting. Creatinine clearance was moderately reduced in ten cases, but no serious renal toxicity was observed. Seizures occurred postoperatively in nine patients. Infrequent side effects were myelosuppression, ototoxicity, and postoperative intracranial bleeding. All adverse effects disappeared with conservative treatment or no intervention.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D001826 Body Fluids Liquid components of living organisms. Body Fluid,Fluid, Body,Fluids, Body
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions

Related Publications

H Nakagawa, and T Fujita, and S Izumoto, and S Kubo, and Y Nakajima, and K Tsuruzono, and K Kodama, and M Higashiyama, and O Doi, and T Hayakawa
[Continuous intravenous infusion therapy of cis-diamminedichloroplatinum (CDDP) in children with neuroblastoma].
October 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
H Nakagawa, and T Fujita, and S Izumoto, and S Kubo, and Y Nakajima, and K Tsuruzono, and K Kodama, and M Higashiyama, and O Doi, and T Hayakawa
Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors.
September 1984, Cancer,
H Nakagawa, and T Fujita, and S Izumoto, and S Kubo, and Y Nakajima, and K Tsuruzono, and K Kodama, and M Higashiyama, and O Doi, and T Hayakawa
Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors.
June 1982, Cancer research,
H Nakagawa, and T Fujita, and S Izumoto, and S Kubo, and Y Nakajima, and K Tsuruzono, and K Kodama, and M Higashiyama, and O Doi, and T Hayakawa
Changes in serum acute phase proteins in ovarian cancer patients receiving cis-diamminedichloroplatinum (CDDP) infusion therapy.
February 1984, Clinical biochemistry,
H Nakagawa, and T Fujita, and S Izumoto, and S Kubo, and Y Nakajima, and K Tsuruzono, and K Kodama, and M Higashiyama, and O Doi, and T Hayakawa
[Cis-diamminedichloroplatinum (CDDP)-radiation therapy of an advanced nasopharyngeal carcinoma].
May 1989, Gan no rinsho. Japan journal of cancer clinics,
H Nakagawa, and T Fujita, and S Izumoto, and S Kubo, and Y Nakajima, and K Tsuruzono, and K Kodama, and M Higashiyama, and O Doi, and T Hayakawa
[Central Nervous System Tumor Brain Metastasis Update: Drug Therapy for Brain Metastases].
June 2022, Gan to kagaku ryoho. Cancer & chemotherapy,
H Nakagawa, and T Fujita, and S Izumoto, and S Kubo, and Y Nakajima, and K Tsuruzono, and K Kodama, and M Higashiyama, and O Doi, and T Hayakawa
Immune Therapy for Central Nervous System Metastasis.
October 2020, Neurosurgery clinics of North America,
H Nakagawa, and T Fujita, and S Izumoto, and S Kubo, and Y Nakajima, and K Tsuruzono, and K Kodama, and M Higashiyama, and O Doi, and T Hayakawa
A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors.
May 1982, Cancer research,
H Nakagawa, and T Fujita, and S Izumoto, and S Kubo, and Y Nakajima, and K Tsuruzono, and K Kodama, and M Higashiyama, and O Doi, and T Hayakawa
Editorial: Mechanisms and Therapy for Cancer Metastasis to the Central Nervous System.
January 2019, Frontiers in oncology,
H Nakagawa, and T Fujita, and S Izumoto, and S Kubo, and Y Nakajima, and K Tsuruzono, and K Kodama, and M Higashiyama, and O Doi, and T Hayakawa
[Characteristics of the lung cancer metastasis to the central nervous system].
August 1974, Vrachebnoe delo,
Copied contents to your clipboard!